The National Cancer Institute (NCI) Cancer Clinical Investigator Team Leadership Award (CCITLA) P30 Administrative Supplement for Fiscal Year (FY) 2021

项目摘要 博士Zahi Mitri是美国医学院血液学和内科肿瘤学系的医学助理教授， 俄勒冈州健康与科学大学（OHSU）的奈特癌症研究所，他是乳腺癌研究的领导者。 癌症研究计划。他在亚特兰大的埃默里大学医院完成了内科住院医师的工作 以及德克萨斯大学MD安德森癌症中心的血液学和医学肿瘤学奖学金。 博士Mitri的热情和兴趣集中在乳腺癌的临床转化研究上，他是一位活跃的 临床试验员;担任以下NCI资助试验的研究中心PI：I-SPY 2、SWOG S1418、SWOG S1501， 和ECOG-ACRIN EA 1183，是6项评价新型抗肿瘤药物的药物启动试验（IIT）的主要研究者。 治疗组合。此外，Mitri博士还担任Knight癌症研究所科学研究中心的联合主席。 审查委员会，是SWOG乳腺癌和转化医学乳腺癌的成员 委员会，SWOG免疫治疗委员会，是SWOG早期研究者代表， NCI乳腺免疫肿瘤学（BIO）工作组 博士Mitri在分子和结构的系列测量的发展中发挥了重要作用。 治疗反应（SMMART）是奈特癌症研究所的旗舰项目，利用强大的 生物标志物平台，为乳腺癌患者提供个性化治疗并改善预后。 利用来自他的IIT的连续活检进行评估，使用SMART的多组学，成像， 生物信息学平台，Mitri博士的研究致力于评估肿瘤细胞的内在特征， 免疫结构，因为它们在治疗应激下进化。特别是，这些努力集中在使用这些 先进的分析工具，以确定对治疗敏感的预测生物标志物，并揭示 治疗耐药性可以为下一代临床试验的发展提供信息。 这些研究活动继续整合乳腺癌领域的各种转化科学 疾病谱，Mitri博士一直致力于建立一个研究平台， 临床和临床前研究者之间的无缝和高效协作。他的最终目标是使 通过临床转化研究对该领域产生积极影响，并领导全国公认的 乳腺癌的个性化治疗方案。癌症临床研究者提供的支持 团队领导奖将是至关重要的博士. Mitri保护所需的时间投入到这些项目.

PROJECT SUMMARY Dr. Zahi Mitri is an Assistant Professor of Medicine in the Division of Hematology and Medical Oncology in the Knight Cancer Institute at Oregon Health & Science University (OHSU) where he is the leader of the breast cancer research program. He completed an Internal Medicine residency at Emory University Hospital in Atlanta and a Hematology and Medical Oncology Fellowship at the University of Texas MD Anderson Cancer Center. Dr. Mitri’s passion and interest is focused on clinical-translational research in breast cancer and he is an active clinical trialist; serving as site PI for the following NCI-funded trials: I-SPY 2, SWOG S1418, SWOG S1501, and ECOG-ACRIN EA1183, and is principal investigator of 6 investigator-initiated trials (IITs) evaluating novel therapeutic combinations. Additionally, Dr. Mitri serves as co-chair of the Knight Cancer Institute’s Scientific Review Committee, and is a member of the SWOG Breast Cancer and Translational Medicine Breast Cancer Committees, SWOG Immunotherapeutics Committee, and is the SWOG Early Investigator Representative on the NCI Breast Immuno-Oncology (BIO) Task Force. Dr. Mitri has been instrumental in the development of the Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART), a flagship program of the Knight Cancer Institute that leverages a robust biomarker platform to deliver personalized therapies and improve outcomes for breast cancer patients. Leveraging serial biopsies from his IITs for evaluation using SMMART’s multi-omics, imaging, and bioinformatics platform, Dr. Mitri’s research endeavors to assess intrinsic tumor cell characteristics and immune contexture as they evolve under therapeutic stress. Particularly, these efforts center on using these advanced analytical tools to identify predictive biomarkers of sensitivity to therapy, and uncover mechanisms of treatment resistance that can inform the development of the next generation of clinical trials. These research activities continue to integrate a variety of translational sciences across the breast cancer disease spectrum and Dr. Mitri has been working towards establishing a research platform that allows for seamless and efficient collaboration between clinical and pre-clinical investigators. His ultimate goal is to make a positive impact on the field through clinical–translational research and to lead a nationally recognized personalized treatment program for breast cancer. The support provided by the Cancer Clinical Investigator Team Leadership Award will be critical for Dr. Mitri to protect the time needed to devote to these projects.